Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiri Minarik

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Annals of Hematology|April 23, 2023
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysisMartin Stork, Ivan Spicka, Jakub Radocha, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Ejhaem|June 9, 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaBarry Paul, Jiri Minarik, Francesca Cottini, et al.
Annals of Hematology|August 18, 2025
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysisMartin Stork, Jakub Radocha, Jana Mihalyova, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.
European Journal of Haematology|October 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow CytometryLudmila Muronova, Ondrej Soucek, David Zihala, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Annals of Hematology|April 23, 2023
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysisMartin Stork, Ivan Spicka, Jakub Radocha, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Ejhaem|June 9, 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaBarry Paul, Jiri Minarik, Francesca Cottini, et al.
Annals of Hematology|August 18, 2025
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysisMartin Stork, Jakub Radocha, Jana Mihalyova, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Annals of Hematology|April 3, 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaEvangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, et al.
Leukemia Research|July 13, 2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma GroupJiri Minarik, Viera Sandecka, Vladimir Maisnar, et al.
European Journal of Haematology|October 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow CytometryLudmila Muronova, Ondrej Soucek, David Zihala, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
Pageof 6